옵션 체인은 다양한 행사가격과 만기일에 대한 Suzano의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Suzano에 대한 시장 심리를 평가합니다..

Suzano (NYSE:SUZ) 주식, 옵션 체인

Suzano

Suzano SA produces and sells pulp and a variety of paper products. The company organizes itself into two segments based on product type: Pulp and Paper. The Pulp segment generates the majority of revenue. The firm's product portfolio includes printing and writing paper, paperboard, diapers, and sanitary napkins. The company owns forest land and plants in Brazil, where it harvests timber and turns the timber into pulp and paper in its plants.

Large Cap

News

Movers

APTV

BGNE

BIRK

MRNA

POOL

이들 10개 대형주는 지난 주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 월그린스 부츠 얼라이언스(NASDAQ:WBA)의 주가는 회사가 혼합된 3분기 실적을 보고하고 2024년 지침을 컨센서스 추정치보다 낮게 낮춘 후 24.12% 하락했다. 분석가들은 주식에 대한 가격 예측을 하향 조정했다.

모더나와 월그린스는 지난주 최악의 성과를 보인 10대 대형주 중 일부 (6월 23일-6월 29일)

ALNY

CVNA

FTAI

MSTR

RDDT

RIVN

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 리비안 오토모티브(NASDAQ:RIVN)는 회사가 생산량을 단순화하고 비용을 절감했으며 폭스바겐과의 합작 투자 계획을 발표했다는 보도가 나온 후 지난주 주가가 30.04% 급등했다. 

리비안과 카바나는 지난주 최고의 성과를 보인 10대 대형주 중 일부 (6월 23일-6월 29일)

ABNB

ALAB

BLDR

EPAM

PLTR

RBLX

SHOP

지난주 성과가 가장 나쁜 대형 주식 10개입니다. 여러분의 포트폴리오에도 들어 있나요?EPAM 시스템즈(NYSE:EPAM)의 주가는 FY24 매출 전망을 낮춘 후 24.6% 하락했다. 몇몇 분석가들은 주식의 목표 가격을 하향 조정했다.

지난주(5월 5일-5월 11일) 최악의 성과를 낸 10개의 대형주

Suzano S.A. American Depositary Shares (each representing One Ordinary Share)

Suzano SA

Sulzer AG

Suzuken Co Ltd

Suzuki Motor Corp

SUZUKI MOTOR CO UNSP/ADR by Suzuki Motor Co.

BofA Securities analyst Brad Sills maintained HubSpot Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) with a Buy and raised the <a target="_blank" href="https://www.benzinga.com/quote/HUBS/analyst-ratings" rel="noreferrer noopener">price target from&nbsp;$780&nbsp;to&nbsp;$850</a>.
Sills hosted CEO Yamini Rangan in investor meetings in Boston on December 12. The analyst remains bullish on HubSpot&#8217;s durability of growth. With its leading cloud platform, HubSpot addresses the vast SMB segment of the $125 billion CRM industry (Gartner).
AI catalyzes market consolidation and expands the TAM to the broader sales services industry. The use cases for HubSpot in the front office offer meaningful value arising from sales productivity gains and revenue uplift. The macro remains essentially unchanged, though there are signs of some improvement.
The rating reflects added confidence that growth will reaccelerate (to the mid-20s in an upside case) from both AI and a better macro as the company moves through fiscal 2025.
HubSpot remains focused on consolidating the SMB portion of the CRM industry (SMB ~55% of total software spending) with a unified platform built for speed and ease of use.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42507816/taiwan-semiconductor-ceo-highlights-ai-powered-drones-next-gen-robots-as-growth-drivers" rel="noreferrer noopener">Taiwan Semiconductor CEO Highlights AI-Powered Drones, Next-Gen Robots As Growth Drivers</a>
Key differentiators are application integration on an organically built platform and channel reach through 6,500 ad agency reseller partners.
HubSpot builds most of its applications on the platform with a common ecosystem, embedded AI, and unified data, per the analyst. This unified platform enables HubSpot to push new agents, copilots, and features to multiple hubs instantly.
When HubSpot makes tuck-in acquisitions, underlying code is rewritten completely on the HubSpot platform to maintain platform discipline.
The HubSpot platform is built for AI-enabled features such as agents and copilots, given one unified dataset, designed for workflow that is simple for SMBs.
HubSpot maintains an agnostic approach to LLMs backing the Breeze AI platform. While OpenAI is the primary model provider, Claude and Gemini are also gaining traction.
If a customer prefers another, HubSpot can accommodate. The company has 90 embedded AI features that are populated into each of the applicable hubs.
Four agents are in beta today: customer (for support), content, social, and prospecting. Customer and support have seen the most traction today.
There are hundreds of customers in beta, to reach thousands. Early adopters of customer agent benefit from 20% to 60% case deflection.
All four agents will likely be generally available in 2025. HubSpot remains in proliferation first, monetize later mode today.
Over time, AI features (copilots, agents, and features) should provide tailwinds across all key growth metrics, such as gross retention, net retention, net adds, and eventually direct monetization via separate offerings.
Today, the focus is on driving value for small businesses via return on investment (ROI) metrics, and these tailwinds should follow.
HubSpot generates extensive unstructured data, such as emails, calls, and PDFs. The Frame AI acquisition provides stream processing to access unstructured data within HubSpot for sentiment and intent analysis.
The combination of structured CRM data and unstructured data represents a comprehensive data set and a meaningful advantage in the AI cycle.
Consistent with comments on the third-quarter earnings call, HubSpot is seeing some improvement in the macro environment, though customers are not yet back in growth mode.
Downgrades have stabilized recently, and the pressure on seat upgrades is improving. However, other upgrades remain softer (cross-sell, contacts, and non-seat-based upgrades) and are still weighing on ASP (-2% Y/Y in the third quarter) and net revenue retention (102%, versus 108%-110% in fiscal 2021 and 2022).
In recent years, HubSpot has invested in partner and sales enablement, which should provide an added tailwind to growth when customers return to growth mode (via sales productivity).
Pricing changes were made in March to enable a lower entry point and drive better, more consistent upgrade momentum.
As part of the pricing change, customers can start with one seat instead of a 5-seat minimum (Pro) and 10-seat minimum (enterprise) for Sales Hub and Service Hub.
HubSpot is already seeing healthy customer upgrade activity on the new pricing, given a lower entry point and upgrade cost on a single seat.
Upgrades will likely increase more meaningfully under the new plan in a better spending environment over a multi-year period.
HubSpot began converting customers to the new pricing during renewals in the summer. Upon the next renewal, HubSpot will convert free administrative users to paid core seats, amounting to a maximum 5% price increase, which should start in the second half of fiscal 2025.
The price target reflects an EV/revenue multiple of 12 times Sills&#8217; calendar 2026 revenue estimate or an EV/revenue/growth multiple of 0.5 times based on his calendar 2026 revenue growth rate of +22%, in line with the large-cap software group.
Sills projected fiscal 2024 revenue of $2.6 billion and EPS of $8.00.
Price Action: HUBS stock is up 2.56% at $740.31 at last check Monday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42489768/cienas-strong-2025-outlook-wins-analyst-confidence-ai-bandwidth-and-optical-market-expansion-in-focus" target="_blank" rel="noreferrer noopener">Ciena&#8217;s Strong 2025 Outlook Wins Analyst Confidence: AI Bandwidth And Optical Market Expansion In Focus</a></li>
</ul>
Photo by Ground Picture on Shutterstock.

Analyst Color

Equities

Price Target

Reiteration

Analyst Ratings

Tech

Trading Ideas

HUBS

HubSpot To Dominate SMB CRM Space With AI-Driven Platform, Says BofA Analyst

<a href="https://www.benzinga.com/general/24/02/36957081/robert-kiyosaki-rich-dad-poor-dad-author-says-i-am-a-billionaire-in-debt-and-calls-dave-ramsey-an-id">Dave Ramsey</a> is a household name in personal finance. Known for his no-debt philosophy and the massive real estate empire he built by paying cash, Ramsey's advice has guided millions toward financial freedom.&nbsp;
But before he became a beacon of financial wisdom, Ramsey <a href="https://www.benzinga.com/startups/24/10/41496567/i-splatted-it-hurt-says-dave-ramsey-referring-to-the-sudden-call-on-his-1-2-million-loans-that-turne">found himself at rock bottom</a>. During a 2023 appearance on The Iced Coffee Hour Podcast, Ramsey opened up about his past financial ruin, the toll it took on his marriage and how he clawed his way back.
Don't Miss:
<ul>
<li>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/1milsaved"> The percentage may shock you</a>.</li>
<li>The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?</li>
</ul>
Confidence to Collapse
"I had hungry kids and a wife that wanted to leave, but she didn't have a car," Ramsey recalled. His confidence and financial stability were shattered. Ramsey once prided himself on his business acumen and admitted that he could "outearn" his poor decisions. But his strategy of leveraging debt backfired, leading to bankruptcy and leaving his family in a state of financial and emotional chaos.
"I wasn't doing any of the right things. <a href="https://www.benzinga.com/personal-finance/24/11/42152386/a-dave-ramsey-caller-opened-up-18-credit-cards-after-bankruptcy-and-is-118000-in-debt-to-impress-people-her-husband-has-no-idea">I was deeply in debt</a>, didn't have a plan and thought I could outearn my stupidity," he admitted. The fallout was devastating and it wasn't just about the money – his self-esteem, his marriage and his family's stability were all hanging by a thread.
See Also: It&#8217;s no wonder Jeff Bezos holds over $70 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a>
Surviving the Storm
When asked how he and his wife, Sharon, managed to hold their marriage together during that time, Ramsey didn't sugarcoat it: "We fought a lot. It was really brutal. She was terrified and my self-esteem was destroyed because my confidence came from my success. When that was gone, I was just a shell."
Despite the tension, they chose to stick together, but it wasn't easy. "We used to laugh and say we held on to each other just to get a better grip," Ramsey said. The couple focused on survival – living day-to-day.
"We just said, ‘Do the next thing.' Get up, go to work, pay the light bill, change the diaper, feed the kids. We were zombified, just grinding it out." Over time, Ramsey began to rebuild financially, eventually pulling in six figures again. But the emotional strain lingered.
Trending: Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.
The Aftermath: A Marriage on the Brink
Surprisingly, Ramsey revealed that the real test of their marriage came three years after their financial recovery. "Once we weren't desperate anymore, all those feelings we had stuffed down just blew up," he said. The couple found themselves in counseling for three years, working through resentment, fear and the deep wounds left by their financial collapse.
"She thought she had married Sir Galahad and it turned out it was Goober," Ramsey said candidly. His wife, Sharon, had to rebuild her trust in him while Ramsey worked on his self-worth.
The Path to Redemption
Ramsey's turnaround wasn't just financial – it was personal and spiritual. "I realized I had put my faith in the wrong things," he said. "If your self-worth is tied to your net worth, you're setting yourself up for failure."
He focused on becoming a person of character, someone his future self could look back on with pride. "I want to be a good dad, a good husband, a good leader. I don't want to live with regrets about my character."
Through their struggles, the Ramseys emerged stronger. With a renewed sense of purpose, Dave began building his debt-free empire, becoming one of the most influential financial advisors in the world.
Trending: Many are using this retirement income calculator to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a>
A Message of Hope
Today, Ramsey's story serves as a powerful reminder that financial ruin doesn't have to be the end of the story. His advice – live on less than you make, avoid debt and stick to a budget – has inspired millions to take control of their money.
But perhaps his greatest lesson is this: perseverance, humility and a commitment to growth can help you rebuild your finances and your life. "When I hear people call in and I can hear that desperation in their voice," he said, "it still hits me in the gut. I've been there."
Dave Ramsey's journey from bankruptcy to financial guru proves that rock bottom isn't permanent – and that it's possible to climb back stronger than ever.
Read Next:
<ul>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a></li>
<li><a href="https://www.benzinga.com/money/62-years-old-with-1-mil-saved">I&#8217;m 62 Years Old And Have $1.2 Million Saved. Is This Enough to Retire Stress-Free?</a></li>
</ul>

Personal Finance

Dave Ramsey Says His Wife Wanted To Leave Him, 'But She Didn't Have A Car' – Hitting Rock Bottom Financially Almost Ended His Marriage

Goldman Sachs analyst Eric Sheridan initiated coverage on Grindr Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRND#NYSE">GRND</a>) with a Buy rating and a <a target="_blank" href="https://www.benzinga.com/quote/GRND/analyst-ratings" rel="noreferrer noopener">price target of&nbsp;$20</a>.
Grindr is an online dating platform primarily focused on serving the LGBTQ+ community with 14.6 million monthly active users (as of the third quarter of 2024) globally.
In this initiation, Sheridan framed his work around three key debates for Grindr stock, including the company&#8217;s addressable market, whether it achieves a 20%+ fiscal 2024-2029 revenue CAGR, and whether it can sustain a 40%+ adjusted EBITDA margin.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42439924/match-group-under-pressure-to-deliver-strategy-for-tinders-struggles-and-hinge-growth-at-investor-meeting" rel="noreferrer noopener">Match Group Faces Investor Scrutiny Over Tinder Woes, Hinge Expansion Plans</a>
Sheridan noted Grindr&#8217;s addressable market as large and growing, as the company is positively leveraged to both the addressable LGBTQ+ user market (his work sizes the 2024 addressable user market at a range of 40 million-80 million) and advertising opportunity.
Grindr modeled fiscal 2024-2029 revenues growing at a 20% CAGR driven mainly by direct revenue (primarily paying user growth) and indirect revenue scaling (advertising).
Sheridan expects adjusted EBITDA margins to remain stable, although margins are unlikely to remain linear as the company focuses on key growth investments over the next 12-18 months.&nbsp;&nbsp;
Based on Sheridan&#8217;s fundamental work, he noted Grindr as a revenue compounder with high margins that are positively leveraged to several long-term secular growth themes and opportunities within online dating. While the online dating sector has been impacted by ongoing investor debates around sources of user growth and user time and engagement, Sheridan noted Grindr as having a user demographic and core proposition that has performed well against such debates (which he expects to persist into 2025 and beyond).&nbsp;&nbsp;
Price Action: GRND stock is up 8.96% at $17.15 at the last check on Monday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/12/42508408/what-is-going-on-with-alibaba-jd-li-auto-xpeng-stocks-on-monday" target="_blank" rel="noreferrer noopener">US-Listed Chinese Stocks React To Underwhelming Consumption Data</a></li>
</ul>
Photo via Shutterstock

Initiation

GRND

Grindr's Expanding LGBTQ+ Market and 20% Revenue Growth Impresses Goldman Sachs

In the current market session, REV Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REVG#NYSE">REVG</a>) stock price is at $34.83, after a 1.14% drop. However, over the past month, the company's stock went up by 18.44%, and in the past year, by 89.91%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2024/1734372909_0.png" alt="Past Year Chart" />

<h3>Evaluating REV Group P/E in Comparison to Its Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 15.94 in the Machinery industry, REV Group Inc. has a lower P/E ratio of 7.46. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1734372909_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

REVG

A Look Into REV Group Inc's Price Over Earnings

<a href="https://electrek.co/2024/12/16/tesla-major-issue-self-driving-computer-inside-new-cars/">https://electrek.co/2024/12/16/tesla-major-issue-self-driving-computer-inside-new-cars/</a>
Brand-new Tesla vehicles are experiencing self-driving computer failures, which are resulting in significant problems. Inside sources say that the problem is contributing to overwhelming Tesla's service.
Over the last few weeks, Electrek has received several reports from new Tesla buyers claiming computer failures on brand-new cars.
We have been investigating the problem, and based on insider sources and documents that we obtained, we can now explain the issue in more detail.
The problem is linked to a new version of Tesla's HW4 (sometimes called AI4) onboard self-driving computer. Internally, some refer to the new version as AI4.1. The computers are short-circuiting. The cause is still being investigated, but one source told Electrek that one of the possible causes is the low-voltage battery short-circuiting the computer during the camera calibration process.
Tesla drivers are reporting computer failures after driving off with their brand-new cars over just the first few tens to hundreds of miles. Wide-ranging features powered by the computer, like active safety features, cameras, and even GPS, navigation, and range estimations, fail to work.
Insider sources told Electrek that the problem is quite wide-ranging. It affects vehicles built over the last few months with the new computer.
Two sources said that Tesla is currently receiving a high number of complaints about this issue, and it has yet to release a service bulletin about it. One source said that Tesla service is being told to play down any safety concerns related to this problem to avoid people believing their brand-new cars are not drivable.
The issue arose at the end of the year when Tesla is trying to deliver a record number of vehicles to avoid its whole year down in deliveries – a first in a decade.
It's unclear if Tesla reported the issue to NHTSA despite the fact that the broken rear-view camera goes against federal safety regulations, which should force a recall.
At the moment, the main remedy being discussed is a computer replacement, but Tesla is also looking to push a software patch to help temporarily.
Tesla service is currently being overwhelmed by the issue, and Tesla is pushing service appointments to next year.

TSLA

'Tesla Is Having Major Issue With Its Self-Driving Computer Inside New Cars' - Electrek

On Friday, Nasdaq Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) annual reconstitution of the Nasdaq-100 Index will become effective before the market opens <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42494812/annual-changes-to-the-nasdaq-100-index" rel="noreferrer noopener">on December 23</a>.
As a result, Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) was&nbsp;removed&nbsp;<a target="_blank" href="https://www.benzinga.com/24/12/42495649/microstrategy-palantir-axon-added-to-nasdaq-100-super-micro-computer-moderna-illumina-exit-the-index" rel="noreferrer noopener">from the index</a>. Year to date, Moderna stock has plunged over 60%, with a 52-week low-high of $35.8-$170.47, as per data from <a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">Benzinga Pro</a>.
Recently, Moderna and several other stocks witnessed a decline as Robert F. Kennedy Jr.'s, Donald Trump's nomination to lead the&nbsp;Department of&nbsp;Health and Human Services, is known to be against vaccines and has a track record of making false <a target="_blank" href="https://www.benzinga.com/24/11/42045488/moderna-remains-confident-despite-political-concerns-over-vaccine-safety-and-hhs-nomination" rel="noreferrer noopener">claims about vaccines</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/42045488/moderna-remains-confident-despite-political-concerns-over-vaccine-safety-and-hhs-nomination" rel="noreferrer noopener">Moderna Remains Confident Despite Political Concerns Over Vaccine Safety and HHS Nomination</a>
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="750" height="650" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16123322/newplot-1-3.png" alt="" class="wp-image-694341" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16123322/newplot-1-3.png 750w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16123322/newplot-1-3-300x260.png 300w" sizes="(max-width: 750px) 100vw, 750px" /></figure>
The company has witnessed a decline in its only approved product, Spikevax, <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40104375/moderna-stock-sinks-on-lowered-2024-outlook-cites-low-european-sales-competitive-rsv-vaccine-mark" rel="noreferrer noopener">the COVID-19 vaccine</a>.
However, Moderna witnessed some relief on higher third-quarter sales attributed to higher sales in the U.S. market following the earlier launch of the <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41854205/modernas-q3-earnings-beat-overshadowed-by-vaccine-demand-slowdown-and-market-share-concerns-analysts-warn" rel="noreferrer noopener">updated COVID-19 vaccine</a>.
Moderna&nbsp;unveiled key updates at its annual R&amp;D Day in September, spotlighting its mRNA-based pipeline and <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40834547/moderna-outlines-post-covid-roadmap-cuts-research-budget-forecasts-2025-sales-below-expectations" rel="noreferrer noopener">revised financial plans</a>.
Faced with commercial challenges, Moderna is adopting a more selective approach to R&amp;D investments. The company anticipates maintaining substantial R&amp;D investment, especially in oncology and rare diseases, while pacing other expenditures.
Moderna is also facing several litigations, including the recently announced patent infringement lawsuit filed by Northwestern University. The lawsuit alleges that the pharmaceutical company used the university's lipid nanoparticle (LNP) technology without permission to develop&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41381861/moderna-hit-with-another-lawsuit-related-to-key-covid-19-vaccine-technology" rel="noreferrer noopener">its COVID-19 vaccines.</a>
GSK Plc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) also filed a lawsuit alleging that Moderna's mRNA vaccines infringe on&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41342286/gsk-sues-moderna-alleging-mrna-vaccine-patent-infringement" rel="noreferrer noopener">patents it developed</a>.
Price Action: MRNA stock is down 1.04% at $41.40 at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42507816/taiwan-semiconductor-ceo-highlights-ai-powered-drones-next-gen-robots-as-growth-drivers" target="_blank" rel="noreferrer noopener">Taiwan Semiconductor CEO Highlights AI-Powered Drones, Next-Gen Robots As Growth Drivers</a></li>
</ul>
Photo via <a href="https://commons.wikimedia.org/wiki/File:Moderna_COVID-19_vaccine_%282021%29_F.jpg">Wikimedia Commons</a>

Biotech

Health Care

General

NDAQ

What's Going On Moderna Stock On Monday?

Lee Enterprises, a leading provider of local news, information, and advertising across 73 markets in the United States, today announced that it has selected Amazon Web Services (AWS) as its Preferred Cloud Provider to modernize its cloud infrastructure and accelerate the development of generative AI (GenAI) platforms. By going all-in on AWS, Lee Enterprises is advancing its digital transformation strategy to enhance subscriber experiences and advertising services through cutting-edge technologies.

Lee Enterprises Selects AWS As Its Preferred Cloud Provider To Modernize Infrastructure And Develop Generative AI Platforms

On Friday, Taiwan Semiconductor Manufacturing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) unveiled its first <a target="_blank" href="https://www.benzinga.com/topic/taiwan" rel="noreferrer noopener">advanced chip fabrication plant</a> in Arizona, marking a significant milestone in U.S.-based semiconductor production.
The facility, covering 3.5 million square feet on a 1,100-acre site, represents Taiwan Semiconductor&#8217;s commitment to bolstering domestic chip manufacturing. Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) is its largest customer.
Initially projected at $12 billion, the project has grown to $20 billion, and production has been delayed to 2025. Taiwan Semiconductor stock is trading upwards on Monday.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42487128/apples-2025-chip-transition-targets-new-wireless-edge-broadcom-to-retain-key-role" rel="noreferrer noopener">Apple&#8217;s 2025 Chip Transition Targets New Wireless Edge, Broadcom To Retain Key Role</a>
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="750" height="650" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16100308/newplot-12.png" alt="" class="wp-image-694092" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16100308/newplot-12.png 750w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16100308/newplot-12-300x260.png 300w" sizes="(max-width: 750px) 100vw, 750px" /></figure>
Currently in pilot production, the fab manufactures sample wafers for customer verification, CNBC <a target="_blank" href="https://www.cnbc.com/2024/12/13/inside-tsmcs-new-chip-fab-where-apple-will-make-chips-in-the-us-.html" rel="noreferrer noopener">reports</a>.
Taiwan Semiconductor plans to build two additional fabs on the site by the end of the decade, bringing the total investment to $65 billion.
Rick Cassidy, chairman of Taiwan Semiconductor, highlighted to CNBC the challenges of navigating U.S. regulations, labor laws, and construction processes but expressed confidence that the project is nearly back on its original schedule.
Once operational, the Arizona plant will produce 4-nanometer chips at a rate of 20,000 wafers per month.
The Arizona fab is part of a broader strategy to diversify chip production outside Taiwan, ensuring supply chain resilience amid geopolitical tensions and natural disasters.
Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) is <a target="_blank" href="https://www.benzinga.com/24/12/42336825/nvidia-could-become-taiwan-semis-3rd-us-plant-customer" rel="noreferrer noopener">weighing the production</a> of the front-end process of Blackwell AI chips at Taiwan Semiconductor&#8217;s Arizona plant.
Currently, 92% of the world&#8217;s most advanced chips are made in Taiwan, prompting Taiwan Semiconductor to ship the aforementioned Blackwell chips back to Taiwan for packaging.
The company aims to employ 6,000 workers for its three planned fabs in Arizona. Taiwan Semiconductor has also implemented water recycling initiatives to manage the 4.7 million gallons required daily for operations, reducing consumption to 1 million through sustainable practices.
Running the first Arizona fab requires significant power—2.85 gigawatt-hours per day, equivalent to the usage of 100,000 homes.
Taiwan Semiconductor is offsetting this demand by purchasing renewable energy credits and utilizing on-site solar energy.
International Data Corp&nbsp;expects&nbsp;Taiwan Semiconductor <a target="_blank" href="https://www.benzinga.com/24/12/42480928/taiwan-semi-set-to-command-67-foundry-market-share-idc" rel="noreferrer noopener">to&nbsp;control a 67%</a> share of the global foundry market in 2025, backed by&nbsp;AI&nbsp;applications and crypto-mining technologies.
Taiwan Semiconductor posted third-quarter revenue of $23.50 billion, up 39%, surpassing guidance and estimates, driven by strong demand for 3nm and 5nm technologies. Needham analyst Charles Shi highlighted Apple&#8217;s significant contribution to the <a target="_blank" href="https://www.benzinga.com/news/24/10/41388050/apples-3nm-push-boosts-taiwan-semis-q3-ai-revenue-set-to-triple-analyst" rel="noreferrer noopener">robust 3nm performance</a>.
Price Action: TSM stock is up 1.67% at $204.29 premarket at last check Monday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/12/42507816/taiwan-semiconductor-ceo-highlights-ai-powered-drones-next-gen-robots-as-growth-drivers" target="_blank" rel="noreferrer noopener">Taiwan Semiconductor CEO Highlights AI-Powered Drones, Next-Gen Robots As Growth Drivers</a></li>
</ul>
Photo by Sundry Photography on Shutterstock

Media

AAPL

NVDA

Taiwan Semiconductor Unveils $20 Billion Arizona Chip Fab, Apple Named Key Customer

Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>) and Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) are gaining momentum as Bitcoin reaches a new all-time high <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42507640/bitcoin-taps-106000-consolidates-at-104000-why-is-btc-going-up">above $107,000</a>.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Market Cap</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.4118</td>
<td>$60.6 billion</td>
<td>+1.9%</td>
<td>-5.5%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00002784</td>
<td>$16.4 billion</td>
<td>+0.4%</td>
<td>-6.5%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Benzinga's technical analysis shows that SHIB's Relative Strength Index (RSI) stands at 42.85.
In a bullish trend, the 40-50 RSI range often serves as support. 
The 50-day Simple Moving Average (SMA) is crossing above the 100-day and 200-day SMAs—a pattern typically indicative of building bullish momentum.
Prominent trader Cold Blooded Shiller <a href="https://x.com/ColdBloodShill/status/1868698606200631582">noted</a> that DOGE is "trading as if it's poised to get an ETF approval before Solana." Meanwhile, crypto trader Jake Wujastyk <a href="https://x.com/Jake__Wujastyk/status/1868481297632707066">emphasized</a> the importance of Dogecoin's volume shelf, predicting that a stronger shelf could fuel a more significant upside move.
Trader Tardigrade also pointed out bullish signs on DOGE's 3-day chart, signaling the potential start of a bull run. "DOGE is pumping soon," he stated.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/hashtag/Dogecoin?src=hash&amp;ref_src=twsrc%5Etfw">#Dogecoin</a> 200 ema is taking off on 3-day chart &#x1f525; This signal indicates the beginning of Bull Run &#x1f680;<a href="https://twitter.com/search?q=%24Doge&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$Doge</a> is pumping soon. <a href="https://t.co/GAEABDlpOm">pic.twitter.com/GAEABDlpOm</a>
&mdash; Trader Tardigrade (@TATrader_Alan) <a href="https://twitter.com/TATrader_Alan/status/1868647305823633714?ref_src=twsrc%5Etfw">December 16, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Statistics: Data from IntoTheBlock reveals a 32.4% drop in SHIB's large transaction volume and a 7.3% decline in daily active addresses. 
Transactions exceeding $100,000 fell from 255 to 145 in a single day. 
However, data from Shibariumscan indicates that daily transactions remain steady at 4.69 million, showcasing consistent network activity.
Crypto analyst Ali Martinez highlighted that 5.8 billion previously idle DOGE tokens were transferred within the past 24 hours, a sign of renewed market interest and activity.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">5.8 billion idle <a href="https://twitter.com/hashtag/Dogecoin?src=hash&amp;ref_src=twsrc%5Etfw">#Dogecoin</a> <a href="https://twitter.com/search?q=%24DOGE&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$DOGE</a> tokens have come to life, changing hands in the past 24 hours. <a href="https://t.co/4gSkVhAAcO">pic.twitter.com/4gSkVhAAcO</a>
&mdash; Ali (@ali_charts) <a href="https://twitter.com/ali_charts/status/1868683748373627196?ref_src=twsrc%5Etfw">December 16, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
What&#8217;s Next: The bullish technical patterns and notable on-chain activity suggest that both Shiba Inu and Dogecoin could see continued upward momentum, especially as market interest surges alongside Bitcoin's record highs.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42421654/dogecoin-drops-14-shiba-inu-sinks-17-whats-behind-the-decline">Dogecoin Drops 14%, Shiba Inu Sinks 17%: What&#8217;s Behind The Decline?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

$SHIB

Shiba Inu Burn Rate Surges 3,609% As Dogecoin Whales Move 5.8 Billion DOGE: What Is Going On?

Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) underwent analysis by 30 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">13</td>
<td align="right">11</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">9</td>
<td align="right">10</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Snowflake, presenting an average target of $183.47, a high estimate of $225.00, and a low estimate of $125.00. This current average has increased by 8.04% from the previous average price target of $169.82. 
<img src="https://www.benzinga.com/files/images/story/2024/1734372049_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The perception of Snowflake by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brent Thill</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$200.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Patrick Colville</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$220.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$190.00</td>
<td>$172.00</td>
</tr>
<tr>
<td>Eric Heath</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$210.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$190.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Announces</td>
<td>Outperform</td>
<td>$190.00</td>
<td>-</td>
</tr>
<tr>
<td>Tyler Radke</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$225.00</td>
<td>$183.00</td>
</tr>
<tr>
<td>Ki Bin Kim</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$210.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Neutral</td>
<td>$160.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Gregg Moskowitz</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$195.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>J. Derrick Wood</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Brad Zelnick</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$188.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Bradley Sills</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$185.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$172.00</td>
<td>$142.00</td>
</tr>
<tr>
<td>Ittai Kidron</td>
<td>Oppenheimer</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$180.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Brent Thill</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$180.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$150.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Kirk Materne</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$190.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Eric Heath</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$185.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Blair Abernethy</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$186.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Mike Cikos</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$200.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$185.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Blair Abernethy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$180.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Tyler Radke</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$183.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Eric Heath</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$150.00</td>
<td>$168.00</td>
</tr>
<tr>
<td>Brian White</td>
<td>Monness, Crespi, Hardt</td>
<td>Announces</td>
<td>Buy</td>
<td>$140.00</td>
<td>-</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$175.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Blair Abernethy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$180.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Karl Keirstead</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$125.00</td>
<td>$155.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Snowflake. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Snowflake compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Snowflake's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Snowflake's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/SNOW/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Snowflake analyst ratings.</a>
<h2>All You Need to Know About Snowflake</h2>
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that went public in 2020. To date, the company has over 3,000 customers, including nearly 30% of the Fortune 500. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to buy and ingest data, while its data solutions can be hosted on various public clouds.
<h3>Understanding the Numbers: Snowflake's Finances</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Snowflake's revenue growth over a period of 3 months has been noteworthy. As of 31 October, 2024, the company achieved a revenue growth rate of approximately 28.32%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: Snowflake's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -34.42%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Snowflake's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -9.19%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Snowflake's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -4.28%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Snowflake's debt-to-equity ratio is below the industry average. With a ratio of 0.89, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SNOW

What Analysts Are Saying About Snowflake Stock

Analysts' ratings for Agilon Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>) over the last quarter vary from bullish to bearish, as provided by 10 analysts.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">2</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">2</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Agilon Health, revealing an average target of $2.58, a high estimate of $4.00, and a low estimate of $1.75. This current average represents a 51.87% decrease from the previous average price target of $5.36. 
<img src="https://www.benzinga.com/files/images/story/2024/1734372042_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Agilon Health among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tao Qiu</td>
<td>Macquarie</td>
<td>Announces</td>
<td>Neutral</td>
<td>$3.00</td>
<td>-</td>
</tr>
<tr>
<td>Lance Wilkes</td>
<td>Bernstein</td>
<td>Announces</td>
<td>Market Perform</td>
<td>$2.50</td>
<td>-</td>
</tr>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$3.00</td>
<td>$3.00</td>
</tr>
<tr>
<td>Daniel Grosslight</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Sell</td>
<td>$1.75</td>
<td>$2.50</td>
</tr>
<tr>
<td>Craig Jones</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$2.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Gary Taylor</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$2.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$2.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Daniel Grosslight</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Sell</td>
<td>$2.50</td>
<td>$7.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$4.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Kevin Fischbeck</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Underperform</td>
<td>$3.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Agilon Health. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Agilon Health compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Agilon Health's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Agilon Health's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/AGL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Agilon Health analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into Agilon Health's Background</h2>
Agilon Health Inc is transforming healthcare by empowering primary care physicians for the health of the patients. The company enables physicians to create their own Medicare-centric globally capitated line of business. The company derives its revenue from Medical services.
<h3>Agilon Health's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Agilon Health's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 27.63% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -8.11%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Agilon Health's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -18.8%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Agilon Health's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -5.53%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Agilon Health's debt-to-equity ratio is below the industry average at 0.08, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 10 Analyst Projections For Agilon Health

Analysts' ratings for Eagle Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXP#NYSE">EXP</a>) over the last quarter vary from bullish to bearish, as provided by 7 analysts.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $314.57, a high estimate of $330.00, and a low estimate of $290.00. Witnessing a positive shift, the current average has risen by 4.31% from the previous average price target of $301.57.
<img src="https://www.benzinga.com/files/images/story/2024/1734372034_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Eagle Materials. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Philip Ng</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$310.00</td>
<td>$330.00</td>
</tr>
<tr>
<td>Adrian Huerta</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$310.00</td>
<td>$290.00</td>
</tr>
<tr>
<td>Garik Shmois</td>
<td>Loop Capital</td>
<td>Maintains</td>
<td>Hold</td>
<td>$315.00</td>
<td>$315.00</td>
</tr>
<tr>
<td>Keith Hughes</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$330.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Jerry Revich</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$317.00</td>
<td>$277.00</td>
</tr>
<tr>
<td>Philip Ng</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$330.00</td>
<td>$309.00</td>
</tr>
<tr>
<td>Adrian Huerta</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$290.00</td>
<td>$270.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Eagle Materials. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Eagle Materials compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Eagle Materials's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Eagle Materials's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/EXP/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Eagle Materials analyst ratings.</a>
<h2>Get to Know Eagle Materials Better</h2>
Eagle Materials Inc produces and sells construction products and building materials. Construction products include cement, slag, concrete, and aggregates and building materials include cement and gypsum wallboard, and are sold to the construction and building industries. The firm organizes itself into two sectors: Heavy Materials, which includes the Cement and Concrete and Aggregates segments, and Light Materials, which includes the Gypsum Wallboard and Recycled Paperboard segments.
<h3>Breaking Down Eagle Materials's Financial Performance</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Eagle Materials displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 0.22%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Materials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Eagle Materials's net margin excels beyond industry benchmarks, reaching 23.01%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 10.32%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Eagle Materials's ROA excels beyond industry benchmarks, reaching 4.66%. This signifies efficient management of assets and strong financial health.
Debt Management: Eagle Materials's debt-to-equity ratio surpasses industry norms, standing at 0.77. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>What Are Analyst Ratings?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

7 Analysts Have This To Say About Eagle Materials

Providing a diverse range of perspectives from bullish to bearish, 19 analysts have published ratings on APA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APA#NASDAQ">APA</a>) in the last three months.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">12</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for APA, revealing an average target of $30.74, a high estimate of $48.00, and a low estimate of $24.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 9.72%. 
<img src="https://www.benzinga.com/files/images/story/2024/1734372026_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The perception of APA by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>William Janela</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$24.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Josh Silverstein</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$27.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Scott Gruber</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$24.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Josh Silverstein</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$28.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$26.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Arun Jayaram</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$25.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Scott Hanold</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$32.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Betty Jiang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$27.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$33.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Biju Perincheril</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$48.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$28.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Paul Cheng</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$27.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$36.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Neil Mehta</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Sell</td>
<td>$26.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Betty Jiang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$30.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$47.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Stephen Richardson</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$33.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$34.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Josh Silverstein</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$29.00</td>
<td>$35.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to APA. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of APA compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for APA's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into APA's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/APA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on APA analyst ratings.</a>
<h2>Unveiling the Story Behind APA</h2>
Based in Houston, APA is an independent exploration and production company. It operates primarily in the US, Egypt, the North Sea, and Suriname. At year-end 2023, proved reserves totaled 807 million barrels of oil equivalent, with net reported production of 405 thousand boe/day that year (64% of which was oil and natural gas liquids, with the remainder natural gas).
<h3>APA's Financial Performance</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: APA displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 9.66%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Energy sector.
Net Margin: APA's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -8.81%, the company may face hurdles in effective cost management.
Return on Equity (ROE): APA's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -4.23%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): APA's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -1.13%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.27, caution is advised due to increased financial risk.
<h2>What Are Analyst Ratings?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing APA: Insights From 19 Financial Analysts

In the last three months, 8 analysts have published ratings on Bicycle Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCYC#NASDAQ">BCYC</a>), offering a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $37.0, a high estimate of $55.00, and a low estimate of $17.00. Observing a downward trend, the current average is 14.81% lower than the prior average price target of $43.43. 
<img src="https://www.benzinga.com/files/images/story/2024/1734372018_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The perception of Bicycle Therapeutics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$33.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Kalpit Patel</td>
<td>B. Riley Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$17.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Sudan Loganathan</td>
<td>Stephens &amp; Co.</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$25.00</td>
<td>-</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$35.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$38.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$38.00</td>
<td>$38.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Bicycle Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Bicycle Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Bicycle Therapeutics's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Bicycle Therapeutics's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BCYC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Bicycle Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Bicycle Therapeutics</h2>
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.
<h3>Bicycle Therapeutics: Delving into Financials</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3 months period, Bicycle Therapeutics faced challenges, resulting in a decline of approximately -50.0% in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Bicycle Therapeutics's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -1898.43%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Bicycle Therapeutics's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -5.96%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Bicycle Therapeutics's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -4.95%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Bicycle Therapeutics's debt-to-equity ratio is below the industry average. With a ratio of 0.01, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BCYC

Breaking Down Bicycle Therapeutics: 8 Analysts Share Their Views

SCHW

URBN

CNBC Halftime Report Final Trades: Urban Outfitters, Impinj, Charles Schwab, BlackRock

Analysts' ratings for Under Armour (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAA#NYSE">UAA</a>) over the last quarter vary from bullish to bearish, as provided by 14 analysts.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">11</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $10.14, a high estimate of $16.00, and a low estimate of $4.00. Witnessing a positive shift, the current average has risen by 16.42% from the previous average price target of $8.71.
<img src="https://www.benzinga.com/files/images/story/2024/1734372009_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A clear picture of Under Armour's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adrienne Yih</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$11.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Alex Straton</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Underweight</td>
<td>$4.00</td>
<td>$4.00</td>
</tr>
<tr>
<td>John Kernan</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$11.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Cristina Fernandez</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Adrienne Yih</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$12.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Jay Sole</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$16.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>John Kernan</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$10.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Will Gaertner</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$11.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Joseph Civello</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$11.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Jonathan Komp</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$10.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Cristina Fernandez</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$8.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>John Kernan</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$8.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Cristina Fernandez</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$8.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Jay Sole</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$12.00</td>
<td>$11.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Under Armour. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Under Armour compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Under Armour's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Under Armour's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/UAA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Under Armour analyst ratings.</a>
<h2>Get to Know Under Armour Better</h2>
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America, Asia-Pacific, Europe, and elsewhere. Consumers of its performance-based clothing and shoes include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996 and is led by controlling shareholder Kevin Plank.
<h3>A Deep Dive into Under Armour's Financials</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Under Armour's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -10.7% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 12.18%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Under Armour's ROE stands out, surpassing industry averages. With an impressive ROE of 8.96%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Under Armour's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.64% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.67, Under Armour adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying Under Armour: Insights From 14 Analyst Reviews

PLBY Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLBY#NASDAQ">PLBY</a>) shares rose following the announcement of an expanded partnership with Byborg Enterprises, which includes a commitment from Byborg to <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42504746/plby-group-closes-strategic-partnership-with-byborg-enterprises-sa" rel="noreferrer noopener">purchase an additional $25 million in equity</a>.
The collaboration includes finalizing a long-term, exclusive licensing agreement and signing a new securities purchase agreement with Byborg.
As per the licensing deal, Byborg will license specific Playboy digital intellectual property and manage Playboy Plus, Playboy TV (both linear and digital), and the Playboy Club.
The recently announced licensing&nbsp;agreement ensures annual minimum guaranteed payments of $20 million to PLBY Group over an initial 15-year term, totaling $300 million, plus <a target="_blank" href="https://www.benzinga.com//node/41651993" rel="noreferrer noopener">25% of the net profits from these businesses.</a>
The agreement also includes the potential for up to nine 10-year extensions, contingent on Byborg meeting certain operational milestones.
PLBY entered into a securities purchase agreement with an affiliate of Byborg, under which the company will sell $25 million in newly issued, unregistered shares of its common stock at $1.50 per share, provided the stock price is at or below $1.65 per share prior to the anticipated filing of the preliminary proxy for a special meeting of stockholders.
This share sale is contingent upon approval from the company&#8217;s stockholders at the special meeting.
The purchase and sale of the additional stock in both scenarios will be contingent on PLBY Group&#8217;s stockholders approving the deal at a special meeting. The transaction is expected to close promptly after receiving stockholder approval.
Ben Kohn, Chief Executive Officer of PLBY Group, said, &#8220;Once the transition is completed (expected to be by June 30, 2025), we will focus on expanding our licensing business and investing in our brand. We expect to take significant costs out of PLBY Group, achieve meaningful EBITDA and be cash flow positive.&#8221;
As previously announced on November 5, 2024, Byborg&nbsp;purchased 14.9 million newly issued, unregistered shares of common stock of PLBY Group for a price of&nbsp;$1.50&nbsp;per share, for a total purchase price of&nbsp;$22.35 million.
Byborg also entered into a standstill agreement capping its total holdings in PLBY Group at&nbsp;29.99%. As a result of the initial equity purchase, beginning in 2025, PLBY Group will appoint a director nominated by Byborg and will also add a mutually agreed new independent director. &nbsp;
Price Action: PLBY shares are up 27.7% at $1.80 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/42512587" target="_blank" rel="noreferrer noopener">Netflix Analyst Say It&#8217;s &#8216;Only Investable&#8217; Media Stock, Projects $150 Million NFL Christmas Day Boost</a></li>
</ul>
Image: Courtesy of PLBY Group.

Offerings

Contracts

Small Cap

Management

PLBY

Why Is Playboy Owner PLBY Group Stock Rocketing Today?

The Federal Reserve is widely expected to announce a 25-basis-point rate cut on Dec. 18, marking its third consecutive reduction after slashing rates by 50 basis points in September <a href="https://www.benzinga.com/topic/interest-rates">and by 25 in November.</a>
Markets have fully priced in this move, assigning nearly a 100% probability, as per CME FedWatch tool. 
But the real story isn't just this rate decision — it's the signals embedded in the Fed's updated Summary of Economic Projections (SEP) and Chair Jerome Powell&#8216;s press remarks that could shape 2025's monetary policy trajectory.
Traders should brace for potential surprises.
<h1 class="wp-block-heading">Inflation's Resurgence Clouds The Fed's Interest-Rate Path</h1>
Recent data have reignited inflation concerns, complicating the Fed's roadmap for future cuts. 
November&#8217;s Consumer Price Index (CPI) rose 2.7% year-over-year, notching its second consecutive increase. Meanwhile, the Producer Price Index (PPI) surged to 3% annually — the fastest since February 2023.
This inflation uptick has already pushed traders to reconsider the pace of cuts next year, with Fed futures currently pricing a 50% chance of another reduction by March 2025, down from higher odds just weeks ago.
The Fed's last SEP, released in September, projected that headline Personal Consumption Expenditure (PCE) inflation would fall to 2.1% by 2025, with Core PCE inflation — a preferred measure — declining from 2.6% in 2024 to 2.2%.
Yet, an upward revision in December could signal the Fed's discomfort with recent price trends, hinting at a more prolonged restrictive stance.
<h1 class="wp-block-heading">Dot Plot Drama: Slower Cuts Ahead?</h1>
The infamous dot plot — showing individual policymakers' views on the future path of rates — will likely take center stage.
In September, the median dot forecasted the fed funds rate down from 4.4% in 2024 to 3.4% by the end of 2025, suggesting 100 basis points of cuts over the next year. 
But if the December update scales back the expected pace of cuts, it could deliver a hawkish jolt to markets.
Goldman Sachs economist David Mericle commented, "We expect the FOMC to signal a slower pace of rate cuts moving forward. Our revised forecast eliminates a January cut in 2025 but maintains cuts in March, June, and September, now projecting a slightly higher terminal rate of 3.5%-3.75%."
&#8220;The FOMC will likely signal that rate cuts will continue in 2025, but at a slower pace than between September and December,&#8221; Comerica Economics stated. 
&#8220;Given current growth and inflation dynamics, we expect that the Fed's rate cuts will then be on pause until March at the earliest,&#8221; Joseph Brusuelas, economist at RSM US LLP, said. 
 According to Brusuelas, the dot plot &#8220;will show a median estimate of next year's federal funds rate of 3.625%, which reflects a 25 basis-point increase from the September forecast.&#8221;
<h1 class="wp-block-heading">Growth And Jobs: What's The Fed Signaling?</h1>
Economic growth and labor market projections could also hold critical clues. 
In September, the Fed anticipated GDP growth of 2% annually through 2025 and 2026, alongside an unemployment rate steady at 4.4% for 2025 and edging down to 4.3% in 2026. If these projections hold steady, it suggests the Fed remains cautiously optimistic about the economy&#8217;s resilience. 
Yet, any significant revisions — particularly on jobs — could heighten market volatility during the final trading days of the year, just as the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) battles for its strongest annual gains since 1998.
&#8220;While everyone embraces the [stock market] bubble, I suggest buying a pacemaker for Christmas as a hedge,&#8221; David Rosenberg, president of Rosenberg Research &amp; Associates Inc., stated on social media X. 
Read Now: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42511277/us-services-sector-booms-at-fastest-pace-since-october-2021-business-activity-leaps-to-over-two-year-highs">US Services Sector Booms At Fastest Pace Since October 2021, Business Activity Leaps To Over Two-Year Highs</a></li>
</ul>
Photo: Shutterstock

Macro Economic Events

Econ #s

Economics

Federal Reserve

Fed Poised To Cut Interest Rates By 0.25% This Week: Here's Why Your Focus Should Shift To Other Signals

WIIM

BBAR

Banco BBVA Argentina shares are trading higher after Morgan Stanley upgraded the stock from Underweight to Overweight.

Grindr shares are trading higher after Goldman Sachs initiated coverage on the stock with a Buy rating and a price target of $20.

HSBC upgraded Suzano (SUZ) to Buy from Hold with a R$72.50 price target Published first on TheFly – the ultimate source for real-time, market-movin...

Suzano upgraded to Buy from Hold at HSBC

Suzano Papel E Celulose ( ($SUZ) ) has released its Q3 earnings. Here is a breakdown of the information Suzano Papel E Celulose presented to its in...

Suzano Reports Strong Q3 Amid Market Expansion

Suzano Papel e Celulose SA (SUZ) has released an update. Suzano Papel e Celulose SA has announced the resignation of Marcelo Bacci from his role as...

Suzano Appoints New Finance Executive Vice-President

Suzano Papel e Celulose SA (SUZ) has released an update. Suzano S.A. has announced the issuance of Panda Bonds worth approximately $165 million in ...

Suzano S.A. Expands Funding with Green Panda Bonds

Suzano Papel e Celulose SA (SUZ) has released an update. Suzano S.A. has announced a significant distribution of interest on equity, totaling BRL 2...

Suzano S.A. Declares Major Equity Interest Distribution

Suzano Papel e Celulose SA (SUZ) has released an update. Suzano S.A. has announced a substantial interest on equity payout of 2.5 billion Brazilian...

Suzano S.A. Declares Major Interest on Equity Payout

Suzano Papel e Celulose SA ( ($SUZ) ) has shared an update. Suzano has revised its capital expenditure (CAPEX) estimate for 2024 to R$17.1 billion,...

Suzano Revises CAPEX Estimates for 2024 and 2025

Suzano Papel e Celulose SA ( ($SUZ) ) has issued an announcement. Suzano S.A. has updated its long-term operational expenditure estimates for its p...

Suzano Updates Pulp Business Expenditure Estimates for 2027

Suzano Papel e Celulose SA ( ($SUZ) ) has shared an update. Suzano Papel e Celulose SA is taking strategic steps to enhance its competitiveness in ...

Suzano Advances Sustainability and Market Expansion Amid Industry Challenges

There's a lot to be optimistic about in the Materials sector as 2 analysts just weighed in on SenesTech (SNES – Research Report) and Suzano Papel e...

Comments

Suzano

Suzano (SUZ) 옵션

Suzano (NYSE:SUZ) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌